COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

INTREPID: Investigation of TRELEGY Effectiveness: Usual Practice Design

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03467425
Recruitment Status : Completed
First Posted : March 16, 2018
Last Update Posted : November 12, 2019
Information provided by (Responsible Party):

Brief Summary:
The primary purpose of this study is to assess the effectiveness of TRELEGY ELLIPTA relative to non-ELLIPTA Multiple Inhaler Triple Therapies (MITT) for Chronic Obstructive Pulmonary Disease (COPD) control within the usual clinical practice setting. The study will be conducted once TRELEGY ELLIPTA has been approved in the countries in which the study will be conducted and is available commercially. This is a randomized, open-label, effectiveness, phase 4 study of 24 weeks' duration in COPD subjects to evaluate TRELEGY ELLIPTA (fluticasone furoate [FF]/vilanterol [VI]/umeclidinium bromide [UMEC]: 100 microgram [mcg]/62.5 mcg/25 mcg) inhalation powder taken once daily using a single ELLIPTA inhaler compared with any non-ELLIPTA MITT in the usual care setting. Effectiveness of TRELEGY ELLIPTA will be assessed by comparing proportion of COPD Assessment Test (CAT) responders at Week 24 between two treatment groups. TRELEGY and ELLIPTA are trademarks of GlaxoSmithKline (GSK) group of companies. The study will enroll approximately 3000 subjects.

Condition or disease Intervention/treatment Phase
Pulmonary Disease, Chronic Obstructive Drug: FF/UMEC/VI Drug: Inhaled Corticosteroid Drug: LAMA Drug: LABA Drug: COPD rescue medications Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 3104 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Subjects will be randomized in a ratio of 1:1 to receive one of the following study treatment regimens: TRELEGY ELLIPTA once daily in the morning or Non-ELLIPTA MITT twice-daily treatment.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: The Clinical Effectiveness of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol in a Single Inhaler (TRELEGY™ ELLIPTA™) When Compared With Non-ELLIPTA Multiple Inhaler Triple Therapies in COPD Patients Within a Usual Care Setting
Actual Study Start Date : April 11, 2018
Actual Primary Completion Date : October 10, 2019
Actual Study Completion Date : October 10, 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: COPD

Arm Intervention/treatment
Experimental: TRELEGY ELLIPTA (FF/UMEC/VI: 100 mcg/62.5 mcg/25 mcg)
Eligible subjects will receive a blended combination of FF in the first strip (100 mcg per blister) and UMEC/VI in second strip (62.5 mcg UMEC per blister and 25 mcg VI per blister), a single inhalation once daily in the morning in the same TRELEGY ELLIPTA Dry Powder Inhaler (DPI) via inhalation route for a period of 24 weeks. Study treatment may be augmented with other prescribed COPD medications such as including rescue medications, which will be prescribed and obtained according to usual practice.
FF is a dry white powder containing 100 mcg GW685698 blended with lactose in one blister in the first strip of the DPI. UMEC/VI is a dry white powder containing 62.5 mcg of UMEC and 25 mcg of VI per blister, both blended together with lactose and magnesium stearate in the second strip of the DPI.

Drug: COPD rescue medications
Rescue medications for COPD will be prescribed and obtained according to usual practice.

Active Comparator: Non-ELLIPTA MITT
Eligible subjects will receive the ICS/LAMA/LABA products twice daily and dosing regimens as prescribed by their physician for a period of 24 weeks. Study treatment may be augmented with other prescribed COPD medications such as including rescue medications, which will be prescribed and obtained according to usual practice.
Drug: Inhaled Corticosteroid
Inhaled Corticosteroid (ICS) as prescribed by the physician.

Drug: LAMA
LAMA as prescribed by the physician.

Drug: LABA
LABA as prescribed by the physician.

Drug: COPD rescue medications
Rescue medications for COPD will be prescribed and obtained according to usual practice.

Primary Outcome Measures :
  1. Number of responders based on CAT at Week 24 [ Time Frame: Week 24 ]
    The CAT is a subject-completed instrument designed to provide a simple and reliable measure of health status in COPD for the assessment and long-term follow-up of the individual subject. The CAT consists of eight items, each formatted on a semantic differential scale. Subjects rated their experience on a 6-point scale for each question, ranging from 0 to 5 with a maximum total score of 40. Higher scores indicate greater disease impact. CAT of each subject was assessed at Baseline (Week 1) and Week 24 or Early withdrawal. Responders are the subjects who will have the change from Baseline of CAT score >=2 at Week 24. Number of responders based on CAT at Week 24 will be presented.

Secondary Outcome Measures :
  1. Change from Baseline in forced expiratory volume in 1 second (FEV1) at Week 24 [ Time Frame: Baseline and Week 24 ]
    FEV1 is the volume of air that can be forced out in one second after taking a deep breath, an important measure of pulmonary function. FEV1 measurements will be obtained using spirometer. For FEV1 determination, at least 3 acceptable spirometry efforts (with no more than 8) should be obtained. The largest FEV1 from the 3 acceptable efforts should be recorded, even if they do not come from the same effort. Baseline was Week 1. Change from Baseline is the difference between Baseline value and post-Baseline value.

  2. Number of subjects making at least 1 critical error in inhalation technique at Week 24 [ Time Frame: Week 24 ]
    At the start of the study, and whenever subjects are issued with a prescription for a new COPD maintenance therapy, the physician (or delegate) will train the subject on the correct use of their inhaler device(s). A critical error is defined as an error that is most likely to result in no or significantly reduced medication being inhaled. If subjects are unable to perform spirometry they may still participate in the critical error assessment. All subjects who have spirometry measured will also have an assessment of critical errors if an appropriate error checklist is available for the study medication they are using for COPD maintenance therapy at Week 24/Early withdrawal visit. Percentage of subjects making at least 1 critical error in inhalation technique at the Week 24 will be presented.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   40 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Capable of giving signed informed consent.
  • Subjects with a documented physician diagnosis of COPD.
  • A score of >=10 on the CAT at screening.
  • Subjects who have a history of treatment with systemic/oral corticosteroids, antibiotics and/or hospitalization for at least one COPD exacerbation in the 3 years prior to randomization. This will be captured through subject recall and/or medical records and must be documented in subject's notes. Prior use of systemic/oral corticosteroids and/or antibiotics alone does not qualify as an exacerbation history unless the use was associated with treatment of worsening symptoms of COPD.
  • Subjects currently receiving one of the non-ELLIPTA maintenance therapies listed below who have been prescribed it continually for at least 16 weeks prior to randomization. Continuous prescription is defined as a minimum of 60 days' prescription cover during the prior 16 weeks. The non-ELLIPTA maintenance therapy must be one of the following: Inhaled Corticosteroid (ICS) in combination with Long-acting Muscarinic Receptor Antagonist (LAMA) and Long Acting Beta-Agonist (LABA) (MITT) or LAMA and LABA used in combination as a dual therapy or LABA and ICS used in combination as a dual therapy. Subjects who are currently on a dual maintenance therapy for COPD must be considered by their physician to require a step-up to triple therapy. The reason for the physician decision to step- up must be documented. Subjects who are receiving only COPD medication on an 'as required' basis are not eligible.
  • Subjects must be aged >=40 years of age at the time of signing the informed consent.

Exclusion Criteria:

  • Women of child bearing potential: Women who are pregnant or lactating or are planning on becoming pregnant during the study.
  • Subjects with any life-threatening condition i.e. low probability, in the opinion of the investigator, of 6-month survival due to severity of COPD or comorbid condition.
  • Subjects with resolution of an exacerbation less than 2 weeks prior to visit 1, must not be randomized. Subjects may be rescreened 2 weeks after resolution of exacerbation (exacerbation is defined by treatment with systemic corticosteroids and/or antibiotic).
  • Subjects with historical or current evidence of uncontrolled or clinically significant disease. Significant is defined as any disease that, in the opinion of the investigator, would put the safety of the subject at risk through participation, or which would affect the effectiveness or safety analysis if the disease/condition exacerbated during the study.
  • A history of allergy or hypersensitivity to any corticosteroid, anticholinergic/muscarinic receptor antagonist, beta2-agonist, lactose/milk protein or magnesium stearate or a medical condition such as narrow-angle glaucoma, prostatic hypertrophy or bladder neck obstruction that, in the opinion of the investigator contraindicates study participation.
  • Subjects who, in the opinion of the treating investigator, are chronic users of oral corticosteroids for respiratory or other indications (if unsure discuss with the medical monitor prior to screening). Chronic use is defined as more than 14 days continuous use during the 12 weeks prior to visit 1.
  • Subjects taking any investigational drug treatment within 30 days prior to Visit 1 or within five half-lives (t½) of the prior investigational study (whichever is the longer of the two).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03467425

Show Show 143 study locations
Sponsors and Collaborators
Layout table for investigator information
Study Director: GSK Clinical Trials GlaxoSmithKline
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: GlaxoSmithKline Identifier: NCT03467425    
Other Study ID Numbers: 206854
2017-004369-29 ( EudraCT Number )
First Posted: March 16, 2018    Key Record Dates
Last Update Posted: November 12, 2019
Last Verified: November 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: IPD for this study will be made available via the Clinical Study Data Request site.
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Informed Consent Form (ICF)
Clinical Study Report (CSR)
Time Frame: IPD will be made available within 6 months of publishing the results of the primary endpoints of the study.
Access Criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by GlaxoSmithKline:
Additional relevant MeSH terms:
Layout table for MeSH terms
Pulmonary Disease, Chronic Obstructive
Lung Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive